ADXS Key Stats
- Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine The Street 03/07 01:00 ET
- Advaxis, Inc. "Advaxis' Immunotherapy and the Tumor Microenvironment" noodls 03/05 16:23 ET
- Advaxis Cancer Immunotherapy Featured on CNN noodls 03/03 08:47 ET
- Faruqi & Faruqi, LLP Launches An Investigation of Advaxis, Inc. For Potential Breaches of Fiduciary Duties by Its Board of Directors noodls 02/28 16:04 ET
- Advaxis (ADXS) Falls After $50M Shelf Filing Street Insider 02/18 17:47 ET
- Advaxis, Inc. - “Advaxis Immunotherapies Complement PD-1 Antibodies” noodls 02/18 13:03 ET
- Aegis Capital Begins Advaxis (ADXS) at Buy; Sees Tech Platform as 'Torjan Horse' to Cancer Street Insider 02/18 08:40 ET
- Aegis Capital Starts Advaxis (ADXS) at Buy Street Insider 02/18 08:12 ET
- Advaxis to Participate in Canaccord Genuity Orphan Drug One-on-One Day noodls 02/18 07:34 ET
- Advaxis's ADXS-HPV Phase 2 Results In Context Yahoo 02/16 10:10 ET
ADXS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Advaxis is down 62.69% over the last year vs S&P 500 Total Return up 24.21%, Alere up 58.08%, and Boston Scientific up 83.45%.
Balance Sheet View Statement
Pro Ratings for ADXS
Pro Strategies Featuring ADXS
Did Advaxis make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: New Jersey
- Incorporation Country: United States
- Incorporation State/Province: Delaware
Advaxis Incorporated is a clinical development stage biotechnology company. The company is engaged in developing safe & effective immunotherapies for cancer & infectious diseases.